Oncopeptides AB (publ)

Company snapshot

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partne

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Oncopeptides AB (publ). Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Oncopeptides AB (publ).

1. Jun 8, 2026 Clinical update

   OP-701 — Phase 1

2. Jun 8, 2026 Clinical update

   Melflufen — Phase 3

View all clinical trial activity →

• What is Oncopeptides AB (publ)?

  Oncopeptides AB (publ) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Multiple Myeloma, Recurrent glioblastoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinic

• Is Oncopeptides AB (publ) publicly traded?

  Oncopeptides AB (publ) appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Oncopeptides AB (publ) develop or market?

  We link 2 drug profile(s) where Oncopeptides AB (publ) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/oncopeptides-ab-publ#company-drugs.

• What are the latest developments for Oncopeptides AB (publ)?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Oncopeptides AB (publ) focus on?

  Oncopeptides AB (publ) focuses on Multiple Myeloma, Recurrent glioblastoma based on our analysis of their pipeline programs and drug development activities.